NovalGen

Executive Summary

NovalGen is a clinical-stage biotechnology company based in London, UK, founded in 2018. The company specializes in developing next-generation multi-specific antibody therapies leveraging its proprietary AutoRegulation (AR) platform technology, which aims to enhance safety and potency for oncology, autoimmune, hematological, and metabolic indications. With a Phase 1-stage pipeline, NovalGen is focused on advancing its lead candidate through initial clinical trials while expanding its platform capabilities. Despite being a private company with limited disclosed financials, NovalGen’s innovative approach to antibody engineering positions it within the competitive multi-specific antibody space, though the lack of publicly available pipeline details and funding history introduces uncertainty regarding near-term milestones and valuation.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Clinical Data Readout for Lead Program55% success
• Q4 2026IND Filing for Second Program40% success
• H2 2026Partnership or Licensing Deal for AR Platform30% success